Noxopharm Ltd
ASX:NOX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Noxopharm Ltd
Cash from Financing Activities
Noxopharm Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Noxopharm Ltd
ASX:NOX
|
Cash from Financing Activities
AU$3.9m
|
CAGR 3-Years
58%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Financing Activities
$150.5m
|
CAGR 3-Years
65%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Financing Activities
-$2.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-18%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash from Financing Activities
AU$9.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Financing Activities
-AU$3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Financing Activities
AU$138.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
29%
|
CAGR 10-Years
32%
|
|
Noxopharm Ltd
Glance View
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Gordon, New South Wales. The company went IPO on 2016-08-09. The firm is focused on the treatment of cancer and cytokine release syndrome or septic shock. The firm is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The firm's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The firm's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).
See Also
What is Noxopharm Ltd's Cash from Financing Activities?
Cash from Financing Activities
3.9m
AUD
Based on the financial report for Dec 31, 2025, Noxopharm Ltd's Cash from Financing Activities amounts to 3.9m AUD.
What is Noxopharm Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-35%
The average annual Cash from Financing Activities growth rates for Noxopharm Ltd have been 58% over the past three years , -35% over the past five years .
